Shared on 31 Oct 25
Fair value Increased 5.26%The fair value estimate for Galderma Group has been raised to CHF 149.91 from CHF 142.41. This change reflects analysts' increased confidence due to positive revisions to growth and margin forecasts, as well as a series of upward price target adjustments from major research firms.
Shared on 17 Oct 25
Fair value Increased 1.22%The analyst price target for Galderma Group has been raised, with new estimates increasing from CHF 140.69 to CHF 142.41. This change reflects analysts' optimism on the company's outlook amid steady growth expectations and supportive recent research updates.
Shared on 27 Aug 25
Fair value Increased 2.70%Analysts have raised Galderma Group's price target to CHF140.69, reflecting strengthened conviction in early Nemluvio traction, robust pipeline execution, and sustained market share gains across dermatology. Analyst Commentary Bullish analysts cite strong early commercial traction and blockbuster potential for Nemluvio following its recent launch.
Shared on 01 Aug 25
Fair value Increased 18%Driven by a substantial increase in net profit margin and a marked reduction in the forward P/E multiple, Galderma Group’s fair value estimate has notably risen to CHF134.24. What's in the News Raised 2025 net sales growth guidance to 12-14% at constant currency, citing strong performance in Injectable Aesthetics and launch of Nemluvio in Therapeutic Dermatology; expects Neuromodulators segment to grow in low ‘teens’ percent for the year.